The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains
Hanks, S. K., Quinn, A. M., & Hunter, T. (1988) · Science · doi:10.1126/science.3291115 · Cited by 5,039
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 1,983
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
Stein, H., Mason, D., Gerdes, J., O'Connor, N., Wainscoat, J., Pallesen, G., Gatter, K., Falini, B., Delsol, G., Lemke, H., et al. (1985) · Blood · doi:10.1182/blood.v66.4.848.848 · Cited by 1,846
Knighton, D. R., Zheng, J., Ten Eyck, L. F., Ashford, V. A., Xuong, N.-H., Taylor, S. S., & Sowadski, J. M. (1991) · Science · doi:10.1126/science.1862342 · Cited by 1,759
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
ERK1/2 MAP kinases: Structure, function, and regulation
Roskoski, R. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.04.005 · Cited by 1,650
Self-citationPhiladelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
GROFFEN, J., STEPHENSON, J., HEISTERKAMP, N., DEKLEIN, A., BARTRAM, C., & GROSVELD, G. (1984) · Cell · doi:10.1016/0092-8674(84)90077-1 · Cited by 1,599
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M., Solomon, B. J., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,309
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Choi, Y. L., Soda, M., Yamashita, Y., Ueno, T., Takashima, J., Nakajima, T., Yatabe, Y., Takeuchi, K., Hamada, T., Haruta, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007478 · Cited by 1,189
Crystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Doebele, R. C., Pilling, A. B., Aisner, D. L., Kutateladze, T. G., Le, A. T., Weickhardt, A. J., Kondo, K. L., Linderman, D. J., Heasley, L. E., Franklin, W. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2906 · Cited by 1,063
Molecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Vande Woude, G. F. (1984) · Nature · doi:10.1038/311029a0 · Cited by 989
PI3K signalling: the path to discovery and understanding
Vanhaesebroeck, B., Stephens, L., & Hawkins, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3290 · Cited by 987
Hubbard, S. R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.18.5572 · Cited by 953
Protein kinases: evolution of dynamic regulatory proteins
Taylor, S. S., & Kornev, A. P. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.09.006 · Cited by 945
Cui, J. J., Tran-Dubé, M., Shen, H., Nambu, M., Kung, P.-P., Pairish, M., Jia, L., Meng, J., Funk, L., Botrous, I., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2007613 · Cited by 932
Oncogenic mutations of ALK kinase in neuroblastoma
Chen, Y., Takita, J., Choi, Y. L., Kato, M., Ohira, M., Sanada, M., Wang, L., Soda, M., Kikuchi, A., Igarashi, T., et al. (2008) · Nature · doi:10.1038/nature07399 · Cited by 916
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Janoueix-Lerosey, I., Lequin, D., Brugières, L., Ribeiro, A., de Pontual, L., Combaret, V., Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008) · Nature · doi:10.1038/nature07398 · Cited by 894
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
Lipson, D., Capelletti, M., Yelensky, R., Otto, G., Parker, A., Jarosz, M., Curran, J. A., Balasubramanian, S., Bloom, T., Brennan, K. W., et al. (2012) · Nature Medicine · doi:10.1038/nm.2673 · Cited by 869
Kornev, A. P., Haste, N. M., Taylor, S. S., & Ten Eyck, L. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607656103 · Cited by 762
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., & Yamamoto, T. (1997) · Oncogene · doi:10.1038/sj.onc.1200849 · Cited by 726
Takeuchi, K., Choi, Y. L., Togashi, Y., Soda, M., Hatano, S., Inamura, K., Takada, S., Ueno, T., Yamashita, Y., Satoh, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3248 · Cited by 717
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
Lawrence, B., Perez-Atayde, A., Hibbard, M. K., Rubin, B. P., Dal Cin, P., Pinkus, J. L., Pinkus, G. S., Xiao, S., Yi, E. S., Fletcher, C. D. M., et al. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64550-6 · Cited by 714
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B., & Los, G. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0365 · Cited by 649
Burningham, Z., Hashibe, M., Spector, L., & Schiffman, J. D. (2012) · Clinical Sarcoma Research · doi:10.1186/2045-3329-2-14 · Cited by 639
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N., & Aoki, Y. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.004 · Cited by 636
Vascular endothelial growth factor (VEGF) signaling in tumor progression
Roskoski, R. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.01.006 · Cited by 599
Self-citationA Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors
Sasaki, T., Koivunen, J., Ogino, A., Yanagita, M., Nikiforow, S., Zheng, W., Lathan, C., Marcoux, J. P., Du, J., Okuda, K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1340 · Cited by 597
Katayama, R., Khan, T. M., Benes, C., Lifshits, E., Ebi, H., Rivera, V. M., Shakespeare, W. C., Iafrate, A. J., Engelman, J. A., & Shaw, A. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019559108 · Cited by 542
Lung cancer: diagnosis and management.
Collins, L. G., Haines, C., Perkel, R. L., & Enck, R. E. (2007) · PubMed · Cited by 541
Lenz, G., & Staudt, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0807082 · Cited by 528
Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X., & Witte, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201062 · Cited by 524
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
Through the “Gatekeeper Door”: Exploiting the Active Kinase Conformation
Zuccotto, F., Ardini, E., Casale, E., & Angiolini, M. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901443h · Cited by 518
Hughes, T. P., Hochhaus, A., Branford, S., Müller, M. C., Kaeda, J. S., Foroni, L., Druker, B. J., Guilhot, F., Larson, R. A., O'Brien, S. G., et al. (2010) · Blood · doi:10.1182/blood-2010-03-273979 · Cited by 489
Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma
Cheson, B. D., & Leonard, J. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708875 · Cited by 438
Anaplastic lymphoma kinase: signalling in development and disease
Palmer, R. H., Vernersson, E., Grabbe, C., & Hallberg, B. (2009) · Biochemical Journal · doi:10.1042/bj20090387 · Cited by 423
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, V. D., Gibbons, D. L., Pérez-Soler, R., & Quintás-Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 418
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
Xin, X., Yang, S., Ingle, G., Zlot, C., Rangell, L., Kowalski, J., Schwall, R., Ferrara, N., & Gerritsen, M. E. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64058-8 · Cited by 396
The ErbB/HER receptor protein-tyrosine kinases and cancer
Roskoski, R. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.150 · Cited by 395
Self-citationMariño-Enríquez, A., Wang, W.-L., Roy, A., Lopez-Terrada, D., Lazar, A. J. F., Fletcher, C. D. M., Coffin, C. M., & Hornick, J. L. (2011) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318200cfd5 · Cited by 389
Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin
Stoica, G. E., Kuo, A., Aigner, A., Sunitha, I., Souttou, B., Malerczyk, C., Caughey, D. J., Wen, D., Karavanov, A., Riegel, A. T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010660200 · Cited by 382
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609412103 · Cited by 379
RAF protein-serine/threonine kinases: Structure and regulation
Roskoski, R. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.07.092 · Cited by 376
Self-citationFusion of the ALK Gene to the Clathrin Heavy Chain Gene, CLTC, in Inflammatory Myofibroblastic Tumor
Bridge, J. A., Kanamori, M., Ma, Z., Pickering, D., Hill, D. A., Lydiatt, W., Lui, M. Y., Colleoni, G. W. B., Antonescu, C. R., Ladanyi, M., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61711-7 · Cited by 359
Stoica, G. E., Kuo, A., Powers, C., Bowden, E. T., Sale, E. B., Riegel, A. T., & Wellstein, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205749200 · Cited by 357
Structure and regulation of Kit protein-tyrosine kinase—The stem cell factor receptor
Roskoski, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.150 · Cited by 345
Self-citationDynamics of the Ras/ERK MAPK Cascade as Monitored by Fluorescent Probes
Fujioka, A., Terai, K., Itoh, R. E., Aoki, K., Nakamura, T., Kuroda, S., Nishida, E., & Matsuda, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509344200 · Cited by 340
Sasaki, T., Okuda, K., Zheng, W., Butrynski, J., Capelletti, M., Wang, L., Gray, N. S., Wilner, K., Christensen, J. G., Demetri, G., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2956 · Cited by 335
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 332
Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Nagaiah, G., Hossain, A., Mooney, C. J., Parmentier, J., & Remick, S. C. (2011) · Journal of Oncology · doi:10.1155/2011/542358 · Cited by 317
Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non–Small Cell Lung Cancers
Lin, E., Li, L., Guan, Y., Soriano, R., Rivers, C. S., Mohan, S., Pandita, A., Tang, J., & Modrusan, Z. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0522 · Cited by 302
Winer, E., Gralow, J., Diller, L., Karlan, B., Loehrer, P., Pierce, L., Demetri, G., Ganz, P., Kramer, B., Kris, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.2134 · Cited by 293
Cools, J., Włodarska, I., Somers, R., et al. (2002) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10033 · Cited by 292
Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S., & Yamamoto, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4181 · Cited by 289
Hernández, L., Pinyol, M., Hernández, S., Beà, S., Pulford, K., Rosenwald, A., Lamant, L., Falini, B., Ott, G., Mason, D. Y., et al. (1999) · Blood · doi:10.1182/blood.v94.9.3265 · Cited by 287
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
Carén, H., Abel, F., Kogner, P., & Martinsson, T. (2008) · Biochemical Journal · doi:10.1042/bj20081834 · Cited by 280
Fusion of ALK to the Ran‐binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor
Ma, Z., Hill, D. A., Collins, M. H., Morris, S. W., Sumegi, J., Zhou, M., Zuppan, C., & Bridge, J. A. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10177 · Cited by 280
Togashi, Y., Soda, M., Sakata, S., Sugawara, E., Hatano, S., Asaka, R., Nakajima, T., Mano, H., & Takeuchi, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031323 · Cited by 267
Defining the conserved internal architecture of a protein kinase
Kornev, A. P., & Taylor, S. S. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.10.017 · Cited by 266
Zhang, Q., Raghunath, P. N., Xue, L., Majewski, M., Carpentieri, D. F., Odum, N., Morris, S., Skorski, T., & Wasik, M. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.466 · Cited by 262
Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T. S., & Mori, S. (1994) · PubMed · Cited by 246
Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum
Debelenko, L. V., Raimondi, S. C., Daw, N., Shivakumar, B. R., Huang, D., Nelson, M., & Bridge, J. A. (2011) · Modern Pathology · doi:10.1038/modpathol.2010.213 · Cited by 244
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, S. C., Wood, A. C., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 237
Treating ALK-positive lung cancer—early successes and future challenges
Camidge, D. R., & Doebele, R. C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.43 · Cited by 236
Evolution of the eukaryotic protein kinases as dynamic molecular switches
Taylor, S. S., Keshwani, M. M., Steichen, J. M., & Kornev, A. P. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2012.0054 · Cited by 233
ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time
Gerber, D. E., & Minna, J. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.033 · Cited by 220
Lovly, C. M., Heuckmann, J. M., de Stanchina, E., Chen, H., Thomas, R. K., Liang, C., & Pao, W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3879 · Cited by 217
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K., Shapiro, D. N., Look, A. T., & Saltman, D. L. (1995) · Science · doi:10.1126/science.267.5196.316-b · Cited by 200
Anaplastic Thyroid Cancers Harbor Novel Oncogenic Mutations of the ALK Gene
Murugan, A. K., & Xing, M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4041 · Cited by 193
ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
Heuckmann, J. M., Hölzel, M., Sos, M. L., Heynck, S., Balke-Want, H., Koker, M., Peifer, M., Weiss, J., Lovly, C. M., Grütter, C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1648 · Cited by 191
ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma
De Paepe, P., Baens, M., van Krieken, H., Verhasselt, B., Stul, M., Simons, A., Poppe, B., Laureys, G., Brons, P., Vandenberghe, P., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1050 · Cited by 191
Bilsland, J. G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K. A., Thakur, M., Beaumont, V., Bonnert, T. P., Heavens, R., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301446 · Cited by 188
Anaplastic large cell lymphoma, ALK-positive
Ferreri, A. J. M., Govi, S., Pileri, S. A., & Savage, K. J. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.02.005 · Cited by 184
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Lee, C. C., Jia, Y., Li, N., Sun, X., Ng, K., Ambing, E., Gao, M.-Y., Hua, S., Chen, C., Kim, S., et al. (2010) · Biochemical Journal · doi:10.1042/bj20100609 · Cited by 182
ALKoma: A Cancer Subtype with a Shared Target
Mano, H. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0009 · Cited by 182
Characterization of the expression of the ALK receptor tyrosine kinase in mice
Vernersson, E., Khoo, N. K. S., Henriksson, M. L., Roos, G., Palmer, R. H., & Hallberg, B. (2006) · Gene Expression Patterns · doi:10.1016/j.modgep.2005.11.006 · Cited by 178
Colleoni, G. W. B., Bridge, J. A., Garicochea, B., Liu, J., Filippa, D. A., & Ladanyi, M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64945-0 · Cited by 174
Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
Bossi, R. T., Saccardo, M. B., Ardini, E., Menichincheri, M., Rusconi, L., Magnaghi, P., Orsini, P., Avanzi, N., Borgia, A. L., Nesi, M., et al. (2010) · Biochemistry · doi:10.1021/bi1005514 · Cited by 173
Protein kinase biochemistry and drug discovery
Schwartz, P. A., & Murray, B. W. (2011) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2011.07.004 · Cited by 168
ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth
Motegi, A., Fujimoto, J., Kotani, M., Sakuraba, H., & Yamamoto, T. (2004) · Journal of Cell Science · doi:10.1242/jcs.01183 · Cited by 167
Kinoshita, K., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Miyagi, T., Kobayashi, T., Takanashi, K., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.021 · Cited by 164
Debelenko, L. V., Arthur, D. C., Pack, S. D., Helman, L. J., Schrump, D. S., & Tsokos, M. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000088856.49388.ea · Cited by 163
Moog-Lutz, C., Degoutin, J., Gouzi, J. Y., Frobert, Y., Carvalho, N. B.-D., Bureau, J., Créminon, C., & Vigny, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501972200 · Cited by 158
Dasgupta, R. A., & Rodeberg, D. A. (2012) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2011.10.007 · Cited by 143
Jazii, F. R. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i44.7104 · Cited by 141
Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma
Lamant, L., Gascoyne, R. D., Duplantier, M.-M., Armstrong, F., Raghab, A., Chhanabhai, M., Rajcan‐Separovic, E., Raghab, J., Delsol, G., & Espinos, E. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10232 · Cited by 141
Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma
Du, X., Hu, H., Lin, D., Xia, S.-H., Shen, X., Zhang, Y., Luo, M., Feng, Y., Cai, Y., Xu, X., et al. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0159-4 · Cited by 136
Wei, L., Hubbard, S. R., Hendrickson, W. A., & Ellis, L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.14.8122 · Cited by 136
Armstrong, F., Duplantier, M.-M., Trempat, P., Hiéblot, C., Lamant, L., Espinos, E., Racaud‐Sultan, C., Allouche, M., Campo, E., Delsol, G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207813 · Cited by 129
Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications
Gaál, J., Flucke, U. E., Roeffen, M. H. S., de Bont, E. S. J. M., Sleijfer, S., Mavinkurve‐Groothuis, A. M. C., Suurmeijer, A. J. H., van der Graaf, W. T. A., & Versleijen‐Jonkers, Y. M. H. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.8588 · Cited by 127
Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor
Panagopoulos, I., Nilsson, T., Domanski, H. A., Isaksson, M., Lindblom, P., Mertens, F., & Mandahl, N. (2005) · International Journal of Cancer · doi:10.1002/ijc.21490 · Cited by 126
Lorén, C. E., Englund, C., Grabbe, C., Hallberg, B., Hunter, T. R., & Palmer, R. H. (2003) · EMBO Reports · doi:10.1038/sj.embor.embor897 · Cited by 123
STI-571: an anticancer protein-tyrosine kinase inhibitor
Roskoski, R. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.08.055 · Cited by 112
Self-citationIdentification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma
Takeuchi, K., Soda, M., Togashi, Y., Ota, Y., Sekiguchi, Y., Hatano, S., Asaka, R., Noguchi, M., & Mano, H. (2010) · Haematologica · doi:10.3324/haematol.2010.033514 · Cited by 110
Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas
Hernández, L., Beà, S., Bellosillo, B., Pinyol, M., Falini, B., Carbone, A., Ott, G., Rosenwald, A., Fernández, A., Pulford, K. A. F., et al. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62574-6 · Cited by 107
A novel KIF5B‐ALK variant in nonsmall cell lung cancer
Wong, D. W., Leung, E. L., Wong, S. K., Tin, V. P., Sihoe, A. D., Cheng, L., Au, J. S. K., Chung, L., & Wong, M. P. (2011) · Cancer · doi:10.1002/cncr.25843 · Cited by 105
An Evolutionary Conserved Role for Anaplastic Lymphoma Kinase in Behavioral Responses to Ethanol
Lasek, A. W., Lim, J. P., Kliethermes, C. L., Berger, K. H., Joslyn, G., Brush, G., Xue, L., Robertson, M. A., Moore, M. S., VRANIZAN, K. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022636 · Cited by 104
ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions
Roosbroeck, K. V., Cools, J., Dierickx, D., Thomas, J., Vandenberghe, P., Stul, M. S., Delabie, J., Wolf‐Peeters, C. D., Marynen, P., & Włodarska, I. (2010) · Haematologica · doi:10.3324/haematol.2009.014761 · Cited by 104
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome Resistance
Lovly, C. M., & Pao, W. J. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003728 · Cited by 101
Sabbatini, P., Korenchuk, S., Rowand, J. L., Groy, A., Liu, Q., Leperi, D., Atkins, C. L., Dumble, M. L., Yang, J., Anderson, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0423 · Cited by 98
Marzec, M., Kasprzycka, M., Liu, X., Raghunath, P. N., Wlodarski, P. K., & Wasik, M. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209843 · Cited by 96
Grant, B. D., & Adams, J. A. (1996) · Biochemistry · doi:10.1021/bi952144+ · Cited by 95
Jung, Y., Kim, P., Jung, Y., Keum, J., Kim, S., Choi, Y. S., Do, I., Lee, J., Choi, S., Kim, S., et al. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21945 · Cited by 95
Sonic Hedgehog Signaling Pathway Is Activated in ALK-Positive Anaplastic Large Cell Lymphoma
Singh, R. R., Cho‐Vega, J. H., Davuluri, Y., Ma, S., Kasbidi, F., Milito, C. B., Lennon, P. A., Drakos, E., Medeiros, L. J., Luthra, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1808 · Cited by 94
Kinoshita, K., Kobayashi, T., Asoh, K., Furuichi, N., Ito, T., Kawada, H., Hara, S., Ohwada, J., Hattori, K., Miyagi, T., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200652u · Cited by 89
Sanders, H. R., Li, H.-R., Bruey, J., Scheerle, J. A., Meloni‐Ehrig, A., Kelly, J. C., Novick, C., & Albitar, M. X. (2011) · Cancer Genetics · doi:10.1016/j.cancergencyto.2010.08.024 · Cited by 88
Tartari, C. J., Gunby, R. H., Coluccia, A. M. L., Sottocornola, R., Cimbro, B., Scapozza, L., Donella‐Deana, A., Pinna, L. A., & Gambacorti-Passerini, C. B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m706067200 · Cited by 84
Participation of ADP Dissociation in the Rate-Determining Step in cAMP-Dependent Protein Kinase
Zhou, J., & Adams, J. A. (1997) · Biochemistry · doi:10.1021/bi971438n · Cited by 83
Cheng, M. M., Quail, M. R., Gingrich, D. E., Ott, G. R., Lü, L., Wan, W., Albom, M. S., Angeles, T. S., Aimone, L. D., Cristofani, F., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0776 · Cited by 70
Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
Jabbour, E., Parikh, S. A., Kantarjian, H., & Cortes, J. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.004 · Cited by 68
Evaluation of EML4-ALK Fusion Proteins in Non–Small Cell Lung Cancer Using Small Molecule Inhibitors
Li, Y., Ye, X., Liu, J., Zha, J., & Pei, L. (2011) · Neoplasia · doi:10.1593/neo.101120 · Cited by 67
Grosso, F., Mariano, M. D., Passoni, L., Luksch, R., Tonini, G. P., & Longo, L. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-525 · Cited by 53
ALK signaling and target therapy in anaplastic large cell lymphoma
Tabbò, F., Barreca, A., Piva, R., & Inghirami, G. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00041 · Cited by 51
Lewis, R. T., Bode, C. M., Choquette, D. M., Potashman, M. H., Romero, K., Stellwagen, J. C., Teffera, Y., Moore, E., Whittington, D. A., Chen, H., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3005866 · Cited by 49
Siebert, R., Gesk, S., Harder, L., et al. (1999) · PubMed · doi:10.1182/blood.v94.10.3614.422a38e_3614_3617 · Cited by 49
Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma
Gao, J., Inagaki, Y., Song, P., Qu, X., Kokudo, N., & Tang, W. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.11.011 · Cited by 46
Ott, G. R., Wells, G. J., Thieu, T. V., Quail, M. R., Lisko, J. G., Mesaros, E. F., Gingrich, D. E., Ghose, A. K., Wan, W., Lü, L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200758k · Cited by 43
Smith, G. F. (2009) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(09)04801-2 · Cited by 39
Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors
Ghosh, G., Lian, X. L., Kron, S. J., & Palecek, S. P. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-95 · Cited by 39
Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas
Bedwell, C., Rowe, D. W., Moulton, D., Jones, G., Bown, N. P., & Bacon, C. M. (2010) · Haematologica · doi:10.3324/haematol.2010.031484 · Cited by 39
Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase
Gingrich, D. E., Lisko, J. G., Curry, M. A., Cheng, M. M., Quail, M. R., Lü, L., Wan, W., Albom, M. S., Angeles, T. S., Aimone, L. D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201550q · Cited by 39
Getting Around PLX4032: Studies Turn Up Unusual Mechanisms of Resistance to Melanoma Drug
Tuma, R. S. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr016 · Cited by 13
Selection of Therapy: Rational Decisions Based on Molecular Events
Khorashad, J. S., & Deininger, M. W. (2011) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2011.09.006 · Cited by 8
Pharmacotherapy Options for Advanced Thyroid Cancer
Lerch, C., & Richter, B. (2011) · Drugs · doi:10.2165/11594890-000000000-00000 · Cited by 5
Cited by
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Self-citationUnderstanding and targeting resistance mechanisms in NSCLC
Rotow, J., & Bivona, T. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.84 · Cited by 972
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Roskoski, R. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104609 · Cited by 559
Self-citationProperties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Self-citation
Metadata
- Authors
- Roskoski, R.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 68
- Issue
- 1
- Pages
- 68-94
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W2052016211
- Cited by
- 303
- References
- 153
- FWCI
- 13.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.